Brittany D. Needham

Brittany D. Needham

Auto-generated profile, based on publicly available information

Brittany D. Needham

Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2013 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
BNBrittany D. Needham
Brittany D. Needham
MTM. Stephen Trent
M. Stephen Trent

14 February 2022 in Nature
Verified
Journal Article
Closed access
PDF file
BNBrittany D. Needham
Brittany D. Needham
MFMasanori Funabashi
Masanori Funabashi
MAMark D. Adame
Mark D. Adame
ZWZhuo Wang
Zhuo Wang
JBJoseph C. Boktor
Joseph C. Boktor
SMSarkis K. Mazmanian
Sarkis K. Mazmanian

11 February 2020 in eLife
Verified
Journal Article
Open access
TSTim Sampson
Tim Sampson
CCCollin Challis
Collin Challis
NJNeha Jain
Neha Jain
AMAnastasiya Moiseyenko
Anastasiya Moiseyenko
MLMark S Ladinsky
Mark S Ladinsky
SMSarkis K Mazmanian
Sarkis K Mazmanian
Amyloids are a class of protein with unique self-aggregation properties, and their aberrant accumulation can lead to cellular dysfunctions associated with neurodegenerative diseases. While genetic and environmental factors can influence amyloid formation, molecular triggers and/or facilitators are not well defined. Growing evidence suggests that non-identical amyloid proteins may accelerate reciprocal amyloid aggregation in a prion-like fashion. While humans encode ~30 amyloidogenic proteins, the gut microbiome also produces functional amyloids. For example, curli are cell surface amyloid proteins abundantly expressed by certain gut bacteria. In mice overexpressing the human amyloid α-synuclein (αSyn), we reveal that colonization with curli-producing Escherichia coli promotes αSyn pathology in the gut and the brain. Curli expression is required for E. coli to exacerbate αSyn-induced behavioral deficits, including intestinal and motor impairments. Purified curli subunits accelerate αSyn aggregation in biochemical assays, while oral treatment of mice with a gut-restricted amyloid inhibitor prevents curli-mediated acceleration of pathology and behavioral abnormalities. We propose that exposure to microbial amyloids in the gastrointestinal tract can accelerate αSyn aggregation and disease in the gut and the brain.

16 October 2020 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
BNBrittany D. Needham
Brittany D. Needham
RKRima Kaddurah-Daouk
Rima Kaddurah-Daouk
SMSarkis K. Mazmanian
Sarkis K. Mazmanian

26 June 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
JMJames T. Morton
James T. Morton
DJDong-Min Jin
Dong-Min Jin
RMRobert H. Mills
Robert H. Mills
YSYan Shao
Yan Shao
GRGibraan Rahman
Gibraan Rahman
GTGaspar Taroncher
Gaspar Taroncher
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by heterogeneous cognitive, behavioral and communication impairments. Disruption of the gut–brain axis (GBA) has been implicated in ASD although with limited reproducibility across studies. In this study, we developed a Bayesian differential ranking algorithm to identify ASD-associated molecular and taxa profiles across 10 cross-sectional microbiome datasets and 15 other datasets, including dietary patterns, metabolomics, cytokine profiles and human brain gene expression profiles. We found a functional architecture along the GBA that correlates with heterogeneity of ASD phenotypes, and it is characterized by ASD-associated amino acid, carbohydrate and lipid profiles predominantly encoded by microbial species in the genera Prevotella, Bifidobacterium, Desulfovibrio and Bacteroides and correlates with brain gene expression changes, restrictive dietary patterns and pro-inflammatory cytokine profiles. The functional architecture revealed in age-matched and sex-matched cohorts is not present in sibling-matched cohorts. We also show a strong association between temporal changes in microbiome composition and ASD phenotypes. In summary, we propose a framework to leverage multi-omic datasets from well-defined cohorts and investigate how the GBA influences ASD.

1 March 2021 in Biological Psychiatry
Verified
Journal Article
Open access
BNBrittany D. Needham
Brittany D. Needham
MAMark D. Adame
Mark D. Adame
GSGloria Serena
Gloria Serena
DRDestanie R. Rose
Destanie R. Rose
GPGregory M. Preston
Gregory M. Preston
SMSarkis K. Mazmanian
Sarkis K. Mazmanian
Autism spectrum disorder (ASD) is a neurodevelopmental condition with hallmark behavioral manifestations including impaired social communication and restricted repetitive behavior. In addition, many affected individuals display metabolic imbalances, immune dysregulation, gastrointestinal dysfunction, and altered gut microbiome compositions. We sought to better understand nonbehavioral features of ASD by determining molecular signatures in peripheral tissues through mass spectrometry methods (ultrahigh performance liquid chromatography-tandem mass spectrometry) with broad panels of identified metabolites. Herein, we compared the global metabolome of 231 plasma and 97 fecal samples from a large cohort of children with ASD and typically developing control children. Differences in amino acid, lipid, and xenobiotic metabolism distinguished ASD and typically developing samples. Our results implicated oxidative stress and mitochondrial dysfunction, hormone level elevations, lipid profile changes, and altered levels of phenolic microbial metabolites. We also revealed correlations between specific metabolite profiles and clinical behavior scores. Furthermore, a summary of metabolites modestly associated with gastrointestinal dysfunction in ASD is provided, and a pilot study of metabolites that can be transferred via fecal microbial transplant into mice is identified. These findings support a connection between metabolism, gastrointestinal physiology, and complex behavioral traits and may advance discovery and development of molecular biomarkers for ASD.